National Jewish Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Jewish Health sits in the top decile of US sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count).
National Jewish Health: 83 sponsored US clinical trials, 7 recruiting.
National Jewish Health sponsors 83 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 60 completed. 5 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis, with 6 trials.
Top-decile sponsor footprint
National Jewish Health ranks in the top decile of sponsors by registered trial count (#271 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
60 of 65 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
83 total, page 2 of 2
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
NCT01950533
Pulmonary Fibrosis Contact Registry
NCT01935726
Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
NCT01736839
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
NCT02169752
Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker
NCT01700257
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
NCT01253473
Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma
NCT01589198
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
NCT01587001
Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension
NCT01491646
Dog Hair Extract Study
NCT01343420
Phase II Study of Digitoxin to Treat Cystic Fibrosis
NCT00782288
Study Comparing In-laboratory Polysomnography Electrocardiogram (PSG ECG) to Simultaneously Recorded In-laboratory ECG on the CPC M1 Device
NCT01234077
Sub-Sensitivity to Long-Acting Bronchodilators (LABA)
NCT01117116
Targeting Oxidative Stress in Chronic Beryllium Disease
NCT01088243
Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis
NCT01107028
Telecommunication Enhanced Asthma Management
NCT00958932
Progression of Airway Obstruction in Childhood Asthma
NCT00873873
Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
NCT00659529
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
NCT00738569
Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)
NCT00700921
Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis
NCT00692796
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
NCT00727285
Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea (The BREATHE Study)
NCT00623246
Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications
NCT00557180
Markers of Airway Inflammation in BAL Fluid From Children With Asthma
NCT00838552
Viral-Related Neutrophil Response and Condition Severity in People With ARDS
NCT00548795
Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis
NCT00560989
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis
NCT00379678
Cell Biology of Steroid Resistant Asthma
NCT00361920
The Effect of Obesity on Lung Functioning
NCT00284895
Effect of CPAP (Continuous Positive Airway Pressure) on Lung Function in Asthmatics With Sleep Apnea
NCT00238069
Evaluating Genes in Sputum to Measure Drug Response in COPD
NCT00233051
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease
NCT00238082
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Jewish Health pipeline
7 recruiting of 83 indexed (8% open); 60 completed (72%).
Phase mix: 5 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Cystic Fibrosis (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Jewish Health: open-pipeline peers nationwide
Peers matched on 83 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Jewish Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 83 trials (± recruiting share)
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- New York University · 83 trials · 30% recruiting
- Teva Pharmaceuticals USA · 83 trials · 0% recruiting
- Seagen · 84 trials · 0% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Institute of Neurological Disorders and Stroke (NINDS) · 8% recruiting · 567 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
Related
What to do with this National Jewish Health page
83 registered trials is a research-attention snapshot, not an endorsement of National Jewish Health or any single study.
- 7 of National Jewish Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis is the condition National Jewish Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Jewish Health pipeline card: 83 registered trials from official public datasets.Report a data error.